The FDA panel recommends emergency approval

A key advisory board to the Food and Drug Administration voted 17-4 on Thursday, with one abstaining, to recommend the approval of Pfizer and BioNTech’s emergency coronavirus vaccine. This is the final step before the FDA issues the final OK for the widespread distribution of the first doses across the state of the United States. One person abstained.

If the FDA accepts the non-binding recommendation of the Advisory Committee on Vaccines and Related Biological Products – which is expected – it would be a defining moment for the Covid-19 pandemic, which infects more than 15.4 million people and around 290,000 in the US Has killed people less than a year.

The committee plays a key role in getting influenza and other vaccines approved in the U.S. and verifying that the shots are safe for public use. While the FDA does not need to follow the advisory committee’s recommendation, it often does.

The FDA could approve the emergency use of Pfizer’s vaccine as early as Friday, committee member James Hildreth told NBC’s Weekend Today on Saturday. An Emergency Authorization (EUA) generally allows a drug or vaccine to be administered to a limited population or environment, e.g. B. to hospital patients, as the authority continues to evaluate safety data.

It is unclear whether the FDA will approve Pfizer and BioNTech’s vaccine for use in certain groups. Some people, including pregnant women and young children, will likely have to wait to receive the vaccine in the United States until Pfizer can complete trials with these specific groups. The FDA said Tuesday that there is currently insufficient data to draw any conclusions about the safety of the vaccine in children under 16, pregnant women, and people with compromised immune systems. Regulators in Canada, the UK, and Bahrain have approved the vaccine for most adults.

The committee recommended emergency approval of the vaccine for people aged 16 and over. Prior to the vote, some experts at the meeting argued to limit the recommendation to people who are at least 18 years old, saying the safety data for 16- and 17-year-olds is “thin”.

“I just want to join this group of people who are committed to this. I think the data is very thin and it is insufficient to say that given the low incidence of disease, we are certain,” said Dr. Mark Sawyer panel member and infectious disease expert at the University of California’s San Diego School of Medicine said at the meeting.

An EUA is not the same as a full authorization, which can typically take months. Pfizer has only submitted safety data for two months, but it typically takes the agency six months for full approval.

In a statement following the vote, Albert Bourla, Pfizer CEO, said the company was “happy” with the vote. “If the FDA approves, be ready to make this vaccine available to the people of the United States to help fight it.” this devastating pandemic. “

US officials say they are ready to distribute the vaccine within 24 hours of approval. The initial doses are capped as production increases. Officials predict it will be months before everyone in the US who wants to be vaccinated is vaccinated. Pfizer has announced that it will ship 50 million doses of vaccine this year, enough to vaccinate 25 million people. The vaccine is expected to be distributed in phases, with the most critical U.S. workers and vulnerable people receiving it first. The Centers for Disease Control and Prevention has provided states with an overview recommending that priority be given to health workers and nursing homes first. However, states may distribute the vaccine at their own discretion.

U.S. officials plan to continue to monitor for side effects of the Pfizer vaccine among the healthcare workers and nursing homes who receive it, said Dr. Nancy Messonnier, director of the CDC’s National Center for Immunization and Respiratory Diseases, during the agency’s meeting on Thursday. The officials will use an SMS system called v-safe, which is designed to provide early warning of possible side effects of the vaccines.

The UK, which approved Pfizer’s emergency vaccine last week, began mass vaccination on Tuesday. The vaccine there will be given to frontline health workers, nursing home workers and those over 80 before it is widely used in the UK population.

Pfizer’s vaccine uses messenger RNA or mRNA technology. It’s a new approach to vaccines that uses genetic material to trigger an immune response. Late-stage clinical trial data shows the Covid vaccine is 95% effective at preventing, safe and appears to ward off serious illness. For maximum effectiveness, the vaccine requires two doses about three weeks apart.

The FDA has announced that it will approve a Covid-19 vaccine that is safe and at least 50% effective. In comparison, the flu vaccine generally reduces the risk of developing influenza by 40% to 60% compared to people who were not vaccinated, according to the CDC.

Two days before the meeting, the FDA posted documents on its website showing that the trial data submitted by Pfizer was consistent with the agency’s recommendations for the emergency. The vaccine was also confirmed to be highly effective with no major safety concerns, and more safety data on the vaccine in children, pregnant women and people with compromised immune systems was needed.

During the meeting, FDA vaccine investigator Dr. Susan Wollersheim found that the study data showed a “numerical imbalance” in Bell’s palsy, a condition that causes temporary weakness or paralysis of the muscles in the face. She said there were four cases in the vaccine group and none in the placebo group. While the incidence of the cases was no higher than that of the general population, the FDA recommended further surveillance if the vaccine is approved for wider use.

Pfizer’s vaccine requires a storage temperature of minus 94 degrees Fahrenheit, which presents potential logistical challenges for rural areas and inner cities that may not have good health infrastructure. For comparison: According to Moderna, the vaccine can be stored for up to six months at minus 4 degrees Fahrenheit.

President Donald Trump’s Czar of Coronavirus Vaccine Dr. Moncef Slaoui said the US should be able to distribute enough coronavirus vaccine doses by the end of February to immunize 100 million Americans, nearly a third of the US population. He said the entire US population could be vaccinated against Covid-19 by June.

Pfizer said last week that its US and European production lines are now complete and it is “confident” of delivering the targeted doses.

– CNBC’s Noah Higgins-Dunn and Will Feuer contributed to this report.

Leave your vote

0 points
Upvote Downvote

Related Articles

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.